The most common reasons patients discontinue (adverse effects, supply issues, cost) are challenges an experienced obesity medicine practice is built to navigate
Recently, a drug targeting the receptors of both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) (tirzepatide) has been introduced to the market, and its indications have expanded to include treating obesity
Math Verification Retatrutide (10 mg + 2 mL): 10,000 mcg 2 mL = 5,000 mcg/mL = 5 mg/mL
Despite which treatment plan is selected, your provider will always offer detailed information and clear next steps
That single math error, made with a perfectly good syringe and perfectly good tirzepatide, sends more researchers back to square one than almost any other mistake in peptide protocols